These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 35251693)

  • 21. Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms.
    Kanoski SE; Ong ZY; Fortin SM; Schlessinger ES; Grill HJ
    Diabetes Obes Metab; 2015 Mar; 17(3):285-93. PubMed ID: 25475828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
    Langer J; Hunt B; Valentine WJ
    J Manag Care Pharm; 2013 Apr; 19(3):237-46. PubMed ID: 23537458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting.
    Kesavadev J; Shankar A; Krishnan G; Jothydev S
    Int J Gen Med; 2012; 5():317-22. PubMed ID: 22536087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity.
    Hasanzad M; Sarhangi N; Nikfar S; Ostad SN; Aghaei Meybodi HR
    J Diabetes Metab Disord; 2020 Dec; 19(2):1863-1872. PubMed ID: 33520865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy.
    Yamamoto T; Fukui T; Higuchi A; Ohara M; Hayashi T; Hirano T
    Diabetol Int; 2016 Dec; 7(4):425-431. PubMed ID: 30603295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis.
    Jiang Y; Liu J; Chen X; Yang W; Jia W; Wu J
    Adv Ther; 2021 Mar; 38(3):1470-1482. PubMed ID: 33582976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liraglutide: A New Option for the Treatment of Obesity.
    Nuffer WA; Trujillo JM
    Pharmacotherapy; 2015 Oct; 35(10):926-34. PubMed ID: 26497479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series.
    Ishii S; Nagai Y; Sada Y; Fukuda H; Nakamura Y; Matsuba R; Nakagawa T; Kato H; Tanaka Y
    J Clin Med Res; 2019 Mar; 11(3):219-224. PubMed ID: 30834046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.
    Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ
    Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes.
    Ten Kulve JS; Veltman DJ; van Bloemendaal L; Barkhof F; Drent ML; Diamant M; IJzerman RG
    Diabetes Care; 2016 Feb; 39(2):214-21. PubMed ID: 26283736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management.
    Manigault KR; Thurston MM
    Consult Pharm; 2016 Dec; 31(12):685-697. PubMed ID: 28074747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting.
    Kaur P; Mahendru S; Mithal A
    Indian J Endocrinol Metab; 2016; 20(5):595-599. PubMed ID: 27730066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes.
    Mosikian AA; Golikova TI; Martjanova MV; Babenko AY
    Future Sci OA; 2022 Mar; 8(3):FSO779. PubMed ID: 35251693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes.
    Kyriakidou A; Kyriazou AV; Koufakis T; Vasilopoulos Y; Grammatiki M; Tsekmekidou X; Avramidis I; Baltagiannis S; Goulis DG; Zebekakis P; Kotsa K
    J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study.
    Inoue K; Maeda N; Fujishima Y; Fukuda S; Nagao H; Yamaoka M; Hirata A; Nishizawa H; Funahashi T; Shimomura I
    Diabetol Metab Syndr; 2014; 6(1):95. PubMed ID: 25237400
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.